Loading organizations...
§ Private Profile · Paris, Ile-de-France, France
AI-first biotech company developing AI foundation models to understand biology across multiple scales for biomedical research and drug discovery.
Based in Paris, France, Bioptimus is an artificial intelligence biotechnology company developing universal foundation models designed to understand biology across molecular, cellular, tissue, and whole organism scales. The enterprise trains advanced generative algorithms on massive multimodal patient datasets to accelerate biomedical research, synthesize new biological proteins, and improve data analysis for complex diseases like cancer. In February 2024, the company emerged from stealth mode after raising $35 million in a seed funding round led by Sofinnova Partners, with additional participation from Bpifrance and Owkin. To support its extensive computational infrastructure and train its massive artificial intelligence biological models, the firm selected Amazon Web Services as its preferred cloud provider. Bioptimus was founded in 2023 by a team of former Google DeepMind and Owkin scientists including Jean-Philippe Vert, Rodolphe Jenatton, David Cahané, and Mathilda Strom.
Bioptimus has raised $76.0M across 2 funding rounds.
Bioptimus has raised $76.0M in total across 2 funding rounds.
Bioptimus has raised $76.0M across 2 funding rounds. Most recently, it raised $41.0M Other Equity in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 14, 2025 | $41M Venture Round | Cathay Innovation | — | Announced |
| Feb 20, 2024 | $35M Seed | Sofinnova Partners | — | Announced |
Bioptimus has raised $76.0M in total across 2 funding rounds.
Bioptimus's investors include Cathay Innovation, Sofinnova Partners.